As the number of cases of infection by the novel coronavirus around the world rises, so are shares of a number of biotech companies with exposure to experimental vaccines (as was the case a few years back during the Ebola crisis). For four such biotech stocks – two of which are up over 250% since the beginning of the year – CLICK HERE.